Patients must not be taking, nor plan to take while on protocol treatment, strong CYPA inhibitors (e.g. boceprevir, cobicistat, danoprevir, elvitegravir/RIT, fluvoxamine, indinavir, itraconazole, ketoconazole, lopinavir/RIT, nefazodone, nelfinavir, posaconazole, ritonavir, telaprevir, telithromycin, tipravavir/RIT, or voriconazole); strong CYPA inducers (e.g. avasimibe, phenytoin, rifampin, rifabutin); potent inhibitors of CYPA (e.g. ciprofloxacin); and/or drugs known to be CYPA substrates with a narrow therapeutic range (e.g., diergotamine, ergotamine) within  days prior to randomization; moderate inhibitors or inducers of isoenzyme CYPA should be avoided, but if necessary can be used with caution
Received cytochrome P A (CYPA) inhibitors (such as fluconazole, ketoconazole, voriconazole, and clarithromycin) within  days of starting venetoclax; received strong CYPA inducers (such as rifampin, rifabutin, phenytoin, carbamazepine, and St. Johns Wort) within  days of starting venetoclax
Co-administration with strong CYPA inducers (e.g., phenytoin, rifampin, carbamazepine, St Johns Wort, bosentan, efavirenz, etravirine, modafinil, and nafcillin), strong CYPA inhibitors (e.g., clarithromycin, indinavir, itraconazole, ketoconazole, lopinavir/ritonavir, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telaprevir, telithromycin, verapamil, and voriconazole), and CYPA substrates (e.g., alfentanil, cyclosporine, dihydroergotamine, ergotamine, everolimus, fentanyl, pimozide, quinidine, sirolimus and tacrolimus)
Patients receiving any medications or substances that are strong inhibitors or inducers of CYPA or CYPC are ineligible; current use of, or intended ongoing treatment with: herbal remedies (e.g., St. Johns wort), or strong inhibitors or inducers of permeability-glycoprotein (Pgp) or breast cancer resistance protein  (Bcrp) should also be excluded; below are a few examples of the agents:\r\n* Strong inducers of CYPA or CYPC:\r\n** Antibiotics: rifamycin class agents (e.g., rifampin, rifabutin, rifapentine)\r\n** Anticonvulsants: carbamazepine, oxcarbazepine, phenobarbital, phenytoin, s-mephenytoin\r\n** Miscellaneous: bosentan, St. John's wort\r\n* Strong inhibitors of CYPA or CYPC\r\n** Antibiotics: clarithromycin, telithromycin, troleandomycin\r\n** Antidepressants: nefazodone\r\n** Antifungals: itraconazole, ketoconazole, posaconazole, voriconazole\r\n** Hyperlipidemia: gemfibrozil\r\n** Antiretroviral: ritonavir, saquinavir, atazanavir\r\n** Miscellaneous: conivaptan
Antifungals: itraconazole, ketoconazole, fluconazole (doses >  mg/day), voriconazole
The concomitant use of strong inhibitors of CYPA (e.g., ketoconazole, itraconazole, clarithromycin, ritonavir, indinavir, nelfinavir and saquinavir) and strong inducers of CYPA (e.g. rifampin, phenytoin, carbamazepine, phenobarbital, St. Johns Wort) is not permitted; it is important to regularly consult a frequently-updated medical reference for a list of drugs to avoid or minimize use of; Patient Drug Information Handout and Wallet Card should be provided to patients; as part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product
Subjects using agents known to inhibit or induce CYPA, such as ketoconazole, itraconazole, erythromycin, or rifampin, within  days prior to study start
Systemic treatment with strong inhibitors or inducers of CYP system should not be used on study including but not limited to fluvoxamine, enoxacin, ciprofloxacin, clarithromycin, telithromycin, itraconazole, voriconazole, ketoconazole, nefazodone, posaconazole, rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital, , bupropion, fluoxetine, paroxetine, ticlopidine, or St. Johns wort Ixazomib has significant drug-drug interactions with strong CYPA inducers. No drug-drug interactions with the CYP screen have been found with ONC, but the analysis of these studies is not complete, so during the study use of inhibitors or inducers of CYP system is excluded. Failure to have fully recovered (i.e., grade  toxicity or less, with the exception of alopecia) from clinically significant effects of prior chemotherapy regardless of interval since last treatment
Current use of any of the following medications: boceprevir, carbamazepine, ciprofloxacin, cobicistat, conivaptan, enzalutamide, fluvoxamine, itraconazole, ketoconazole, mitotane, phenytoin, posaconazole, rifampin, ritonavir, St. Johns Wort, telaprevir, voriconazole, or zafirlukast
Subject has used strong cytochrome P (CYP) A inhibitors or inducers such as ketoconazole, rifampin/rifampicin, long acting barbiturates, carbamazepine and St. John's wort in the  days prior to the first administration of study drug.
Current or anticipated use of the following P gp inhibitors (amiodarone, carvedilol, clarithromycin, cobicistat, darunavir, dronedarone, erythromycin, indinavir, itraconazole, ketoconazole, lapatinib, lopinavir, propafenone, quinidine, ranolazine, ritonavir, saquinavir, telaprevir, tipranavir, verapamil, and valspodar), P gp inducers (avasimibe, carbamazepine, phenytoin, rifampin, and St. John's wort), or BCRP inhibitors (curcumin, cyclosporine, elacridar [GF] and eltrombopag).
The subject requires chronic concomitant treatment of strong cytochrome P, family , subfamily A polypeptide  (CYPA) inducers (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentine, phenobarbital, and St. Johns Wort); the subject requires chronic concomitant treatment of strong CYPA inhibitors (e.g., indinavir, nelfinavir, ritonavir, clarithromycin, itraconazole, ketoconazole, nefazodone, saquinavir, telithromycin, aprepitant, erythromycin, fluconazole, grapefruit juice, verapamil, diltiazem, cimetidine, amiodarone, chloramphenicol, boceprevir, ciprofloxacin, delavirdine, diethyl-dithiocarbamate, fluvoxamine, gestodene, imatinib, mibefradil, mifepristone, norfloxacin, norfluoxetine, starfruit, telaprevir, voriconazole); as part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product
Patients require chronic concomitant treatment of strong CYP A inducers (e.g. dexamethasone, phenytoin, carbamazepine, rifampicin, rifabutin, rifapentine, phenobarbital, St. Johns wort) or inhibitors (eg. ketoconazole, miconazole, itraconazole, voriconazole, posaconazole, clarithromycin, telithromycin, indinavir, saquinavir, ritonavir, nelfinavir, amprenavir, fosamprenavir nefazodone, lopinavir, troleandomycin, mibefradil and conivaptan)
Patients must stop taking phenytoin, rifampicin, rifapentine, rifabutin, carbamazepine, nevirapine, modafinil and St Johns wort (hypericum perforatum)  weeks prior to registration; patients must stop taking phenobarbitone  weeks prior to registration; patients must stop taking all strong CYPA inhibitors, including clarithromycin, telithromycin, nefazodone, itraconazole, ketoconazole, atazanavir, darunavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir, and tipranavir, prior to registration
Concomitant medications: the following medicines should be avoided on this study:\r\n* Inhibitors: ketoconazole and other imidazole antifungals, erythromycin, fluoxetine, gemfibrozil, cimetidine, ritonavir, saquinavir, indinavir, and nelfinavir\r\n* Inducers: rifampicin, carbamazepine, phenytoin, efavirenz, and nevirapine\r\n* Patients receiving any of the above medications are ineligible
Received cytochrome P, family , subfamily A (CYPA) inhibitors (such as fluconazole, ketoconazole, voriconazole, and clarithromycin) within  days of starting study drugs; received strong CYPA inducers (such as rifampin, rifabutin, phenytoin, carbamazepine, and St. Johns wort) within  days of starting study drugs
Subjects taking the following are not eligible:\r\n* Carbamazepine (e.g., Tegretol)\r\n* Rifabutin (e.g., Mycobutin) or\r\n* Rifampin (e.g., Rifadin)\r\n* Rifapentine (e.g., Priftin)\r\n* St. John's wort\r\n* Clarithromycin (e.g., Biaxin)\r\n* Cyclosporine (e.g. Neoral or Sandimmune)\r\n* Diltiazem (e.g., Cardizem)\r\n* Erythromycin (e.g., Akne-Mycin, Ery-Tab)\r\n* Itraconazole (e.g., Sporanox)\r\n* Ketoconazole (e.g., Nizoral)\r\n* Telithromycin (e.g., Ketek)\r\n* Verapamil (e.g., Calan sustained release [SR], Isoptin, Verelan)\r\n* Voriconazole (e.g., VFEND)\r\n Tacrolimus (e.g. Prograf)
Subjects taking fluconazole, voriconazole, itraconazole, posaconazole, and ketoconazole within  hours of study drug starting are not eligible; reinstitution of fluconazole, voriconazole, itraconazole, posaconazole, ketoconazole and diltiazem is permissible  hours after the last dose of sirolimus
Present use or anticipated need for cytochrome P (CYP) family , subfamily A, polypeptide  (A)-inhibiting, CYPA-inducing drugs (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, and voriconazole, rifampin, phenytoin, carbamazepine, rifabutin, rifapentine, phenobarbital, and St. John's wort, bosentan, efavirenz, etravirine, modafinil, and nafcillin)
Patients receiving concomitant treatment with strong cytochrome P family  subfamily A member  (CYPA) inhibitors, unless such drugs are considered critical for the well being of the patient and not adequate alternatives are available; strong CYPA inhibitors include the following medications: itraconazole, ketoconazole, miconazole, voriconazole; amprenavir, atazanavir, fosamprenavir, indinavir, nelfinavir, ritonavir; ciprofloxacin, clarithromycin, diclofenac, doxycycline, enoxacin, isoniazid, ketamine, nefazodone, nicardipine, propofol, quinidine, telithromycin
Caution should be exercised when administering paclitaxel (Taxol) concomitantly with medicines known to inhibit (e.g. ketoconazole and other imidazole antifungals, erythromycin, fluoxetine, gemfibrozil, cimetidine, ritonavir, saquinavir, indinavir and nelfinavir) OR induce (e.g. rifampicin, carbamazepine, phenytoin, efavirenz and nevirapine) either CYPC or CYPA. Based on the in vitro data and SimCYP simulations, selumetinib is considered unlikely to perpetrate clinically significant drug-drug interaction via inhibition or induction of CYP enzymes
Caution should be exercised when administering paclitaxel (Taxol) concomitantly with medicines known to inhibit (e.g. ketoconazole and other imidazole antifungals, erythromycin, fluoxetine, gemfibrozil, cimetidine, ritonavir, saquinavir, indinavir and nelfinavir) OR induce (e.g. rifampicin, carbamazepine, phenytoin, efavirenz and nevirapine) either CYPC or CYPA.
Concomitant medications \r\n* Corticosteroids: subjects receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least  days prior to enrollment are not eligible\r\n* Investigational drugs: subjects who are currently receiving another investigational drug are not eligible\r\n* Anti-cancer agents: subjects who are currently receiving other anti-cancer agents are not eligible\r\n* Anti-graft-versus-host disease (GVHD) agents post-transplant: subjects who are receiving cyclosporine, tacrolimus, or other agents to prevent graft-versus-host disease post bone marrow transplant are not eligible for this trial\r\n* Study specific: subjects who are unable to swallow a tablet or swallow liquid are still eligible provided they have a nasogastric (NG) or gastric (G) tube through which the medicine can be administered\r\n* Cytochrome P, family , subfamily A, polypeptide  (CYPA) inhibitors: subjects chronically receiving drugs that are known potent CYPA inhibitors within  days prior to study enrollment, including but not limited to ketoconazole, itraconazole, miconazole, clarithromycin, erythromycin, ritonavir, indinavir, nelfinavir, saquinavir, amprenavir, delavirdine, nefazodone, diltiazem, verapamil, and grapefruit juice are not eligible; the topical use of these medications (if applicable), e.g. % ketoconazole cream, is allowed\r\n * CYPA inducers: subjects chronically receiving drugs that are known potent CYPA inducers within  days prior to study enrollment, including but not limited to carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin, tipranavir, ritonavir, and St. Johns wort are not eligible
Receiving drugs known to be strong inducers or inhibitors of permeability (P)-glycoprotein that are known to interact with afatinib including, but not limited to: ritonavir, cyclosporine A, ketoconazole, itraconazole, erythromycin, verapamil, quinidine, tacrolimus, nelfinavir, saquinavir, and amiodarone; as part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product; the subject must stop the strong inducer or inhibitor of P-glycoprotein  days before or  half lives before study drug administration (whichever timepoint is longer)
Patients receiving strong inhibitors of cytochrome P family , subfamily A, polypeptide  (CYPA)\r\n* Use of the following strong or moderate inhibitors are prohibited =<  days prior to registration\r\n** Boceprevir (Victrelis)\r\n** Clarithromycin (Biaxin, Biaxin XL)\r\n** Conivaptan (Vaprisol)\r\n** Itraconazole (Sporanox)\r\n** Ketoconazole (Nizoral)\r\n** Nefazodone (Serzone)\r\n** Posaconazole (Noxafil)\r\n** Telithromycin (Ketek)\r\n** Voriconazole (Vfend)\r\n* Use of the following inducers are prohibited =<  days prior to registration\r\n** Bosentan (Tracleer)\r\n** Carbamazepine (Carbatrol, Epitol, Equetro, Tegretol, Tegretol-XR)\r\n** Modafinil (Provigil)\r\n** Phenobarbital (Luminal)\r\n** Phenytoin (Dilantin, Phenytek)\r\n** Rifabutin (Mycobutin)\r\n** Rifampin (Rifadin)\r\n** St. Johns wort
Patients may not take any of the following medications while on study, but will be considered eligible if medication is discontinued  hours prior to first dose of sirolimus:\r\n* Carbamazepine (e.g. Tegretol)\r\n* Rifabutin (e.g. Mycobutin)\r\n* Rifampin (e.g. Rifadin)\r\n* Rifapentine (e.g. Priftin)\r\n* St. Johns wort\r\n* Clarithromycin (e.g. Biaxin)\r\n* Cyclosporine e.g. (Neoral or Sandimmune)\r\n* Diltiazem (e.g. Cardizem)\r\n* Erythromycin (e.g. Akne-Mycin, Ery-Tab)\r\n* Itraconazole (e.g. Sporanox)\r\n* Fluconazole (e.g. Diflucan)\r\n* Ketoconazole (e.g. Nizoral)\r\n* Telithromycin (e.g. Ketek)\r\n* Verapamil (e.g. Calan SR, Isoptin, Verelan)\r\n* Voriconazole (e.g. VFEND) - can take  hours after last dose of sirolimus\r\n* Tacrolimus (e.g. Prograf)
Subject is receiving potent inhibitors of cytochrome P, family , subfamily A, polypeptide  (CYPA); for such medications, a wash-out period of >=  days is required prior to starting dasatinib unless discontinuation or substitution of such an inhibitor is not in the best interest of the patient as determined by the investigator; these include the following medications: itraconazole, ketoconazole, miconazole, voriconazole; amprenavir, atazanavir, fosamprenavir, indinavir, nelfinavir, ritonavir; ciprofloxacin, clarithromycin, diclofenac, doxycycline, enoxacin, isoniazid, ketamine, nefazodone, nicardipine, propofol, quinidine, telithromycin; in instances where use of these agents is felt to be required for the best management of the patients, inclusion of such a patients should be discussed with principal investigator (PI) and the rationale documented
Copanlisib is primarily metabolized by CYPA; therefore, the concomitant use of strong inhibitors of CYPA (e.g., ketoconazole, itraconazole, clarithromycin, ritonavir, indinavir, nelfinavir and saquinavir), and strong inducers of CYPA (e.g. rifampin, phenytoin, carbamazepine, phenobarbital, St. Johns Wort) are not permitted from  days prior to enrollment until the end of the study\r\n* Other medications that are prohibited while on copanlisib treatment: \r\n** Herbal medications/preparations (except for vitamins)\r\n** Anti-arrhythmic therapy other than beta blockers or digoxin
Participants receiving any medications or substances that have antiviral activity against KSHV or that are strong inhibitors or inducers of cytochrome P, family , subfamily A (CYPA) or cytochrome P, family , subfamily C, polypeptide  (C) are ineligible; each ART regimen must be reviewed by the PI before determining eligibility to receive nelfinavir mesylate (NFV); sensitive substrates should be avoided; of the antiretroviral drugs, only delaviridine, nevirapine, cobicistat-boosted antiretrovirals (strong CYPA inhibitor), maraviroc (sensitive CYPA substrate), and PIs (strong CYPA inhibitor) are excluded; the following drugs are also prohibited:\r\nStrong Inhibitors of CYPA:\r\n* Antibiotics: clarithromycin, erythromycin, telithromycin, troleandomycin\r\n* HIV: non-nucleoside reverse transcriptase inhibitors (delaviridine, nevirapine), protease inhibitors (ritonavir, indinavir, lopinavir/ritonavir, saquinavir), cobicistat-boosted antiretrovirals (e.g., elvitegravir); NOTE: Clinical trials have demonstrated that there are no clinically significant drug-drug interactions between nelfinavir and the following antiretrovirals: efavirenz (strong CYPA inhibitor), etravirine (strong CYPA inhibitor); therefore, these antiretrovirals will not be excluded\r\n* Antifungals: itraconzaole, ketoconazole, voriconazole, fluconazole, posaconazole\r\n* Antidepressants: nefazodone\r\n* Antidiuretic: conivaptan\r\n* GI: cimetidine, aprepitant\r\n* Hepatitis C: boceprevir, telaprevir\r\n* Miscellaneous: seville oranges, grapefruit, or grapefruit juice and/or pummelos, star fruit, exotic citrus fruits, or grapefruit hybrids\r\nStrong Inducers of CYPA:\r\n* Glucocorticoids: cortisone (>  mg), hydrocortisone (>  mg), prednisone (>  mg), methylprednisolone (>  mg), dexamethasone (> . mg)\r\n* Anticonvulsants: phenytoin, carbamazepine, primidone, phenobarbital and other enzyme inducing anti-convulsant drugs (EIACD)\r\n* Antibiotics: rifampin (rifampicin), rifabutin, rifapentine\r\n* Miscellaneous: St. Johns Wort, modafinil\r\nStrong Inhibitors of CYPC:\r\n* Antifungals: fluconazole; lists including medications and substances known or with the potential to interact with the CYPA or C\r\nDrugs with KSHV antiviral activity:\r\n* Participants receiving any medications or substances that may interfere with KSHV replication are ineligible\r\nBecause the lists of these agents are constantly changing, it is important to regularly consult a frequently-updated list; medical reference texts such as the physicians desk reference may also provide this information; as part of the enrollment/informed consent procedures, the participant will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the participant is considering a new over-the-counter medicine or herbal product; lists include medications and substances known or with the potential to interfere with KSHV replication
Strong CYPA inhibitors and inducers; concomitant use of strong inhibitors of CYPA (e.g., ketoconazole, itraconazole, clarithromycin, ritonavir, indinavir, nelfinavir and saquinavir), and inducers of CYPA (e.g., rifampin, phenytoin, carbamazepine, phenobarbital, St. John's Wort) are not permitted within two weeks prior to start of study treatment and for the duration of treatment with copanlisib
Selected strong inhibitors of cytochrome P, family , subfamily A, polypeptide  (cytochrome P A) include azole antifungals, such as fluconazole, voriconazole, itraconazole, ketoconazole, and strong inducers include drugs such as rifampin, phenytoin, phenobarbitol, carbamazepine, and St. Johns wort; the use of these drugs should be avoided with vincristine (vincristine sulfate)
Clinically significant drug interactions have been reported when using vincristine with strong cytochrome P (CYP) family  subfamily A member  (A) inhibitors and inducers; selected strong inhibitors of cytochrome P A include azole antifungals, such as fluconazole, voriconazole, itraconazole, ketoconazole, and strong inducers include drugs such as rifampin, phenytoin, phenobarbitol, carbamazepine, and St. Johns wort; the use of these drugs should be avoided with vincristine
Drugs that potently inhibit or induce CYPA should be administered with caution; below are a few examples of the agents:\r\n* Drugs that may increase exposure of trametinib (CYPA inhibitors):\r\n** Antivirals: amprenavir, atazanavir, fosamprenavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir\r\n** Antibiotics: clarithromycin, erythromycin, telithromycin, troleandomycin\r\n** Antifungals: fluconazole, itraconazole, ketoconazole, voriconazole\r\n** Antidepressants: nefazodone\r\n** Calcium channel blockers: mibefradil, diltiazem, verapamil\r\n** Miscellaneous: aprepitant\r\n* Drugs that may decrease exposure of trametinib (CYPA inducers)\r\n** Antivirals: efavirenz, nevirapine\r\n** Antibiotic: rifampin\r\n** Anticonvulsants: carbamazepine, phenobarbital, phenytoin\r\n* Caution should be exercised when dosing trametinib concurrently with medications with narrow therapeutic windows that are substrates of CYPC; below are a few examples of the agents\r\n** Drug metabolism potentially affected by trametinib resulting in increased exposure of these substrates\r\n*** -hydroxy--methyl-glutaryl-CoA (HMG CoA)-reductase inhibitors: cerivastatin\r\n*** Thiazolidinediones: rosiglitazone, pioglitazone\r\n*** Miscellaneous: chloroquine, zopiclone, repaglinide\r\n* As part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product
Patients requiring comedication with potent P-glycoprotein (P-gp) inhibitors (including cyclosporine, azithromycin, erythromycin, ketoconazole, itraconazole, quinidine, phenobarbital salt with quinidine, ritonavir, valspodar, verapamil) or inducers (including rifampicin)
Current use of a prohibited medication; patients receiving any medications or substances that are strong inhibitors or inducers of cytochrome P, family , subfamily A (CYPA) or cytochrome P, family , subfamily C, polypeptide  (CYPC) are ineligible; current use of, or intended ongoing treatment with: herbal remedies (e.g., St. Johns wort), or strong inhibitors or inducers of P-glycoprotein (Pgp) or breast cancer resistance protein  (Bcrp) should also be excluded; it is important to regularly consult a frequently-updated list of these agents; as part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product\r\n* Prohibited: strong inducers of CYPA or CYPC\r\n** Antibiotics: rifamycin class agents (e.g., rifampin, rifabutin, rifapentine)\r\n** Anticonvulsant: carbamazepine, oxcarbazepine phenobarbital, phenytoin, s-mephenytoin\r\n** Miscellaneous: bosentan, St. Johns wort\r\n* Prohibited: strong inhibitors of CYPA or CYPC\r\n** Antibiotics: clarithromycin, telithromycin, troleandomycin\r\n** Antidepressant: nefazodone\r\n** Antifungals: itraconazole, ketoconazole, posaconazole, voriconazole\r\n** Hyperlipidemia: gemfibrozil\r\n** Antiretroviral: ritonavir, saquinavir, atazanavir\r\n** Miscellaneous: conivaptan
Drugs that potently inhibit cytochrome P family , subfamily A, polypeptide  (CYPA) should be prohibited or used with caution; drugs which are strong inducers of CYPA and may result in lower exposures of GSK should also be prohibited; drugs that are substrates of CYPA or cytochrome P family , subfamily C, polypeptide  (CYPC) with a narrow therapeutic index may be prohibited; drugs that are sensitive substrates of CYPA or CYPC should be used with caution\r\n* Caution should be exercised when dosing trametinib concurrently with medications with narrow therapeutic windows that are substrates of CYPC; drugs that potently inhibit or induce CYPA should be administered with caution\r\n* Because the lists of these agents are constantly changing, it is important to regularly consult a frequently-updated list such as http://medicine.iupui.edu/clinpharm/ddis/table.aspx; medical reference texts such as the Physicians Desk Reference may also provide this information; as part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product\r\n* The following medications (including but not limited to) are prohibited during the study:\r\n** PROHIBITED-highly sensitive and/or low therapeutic index\r\n*** Cisapride\r\n*** Pimozide\r\n*** Astemizole\r\n*** Rosuvastatin, sulfasalazine\r\n** PROHIBITED-strong inducers/inhibitors of CYPA\r\n*** Clarithromycin, telithromycin, rifamycin class agents (e.g., rifampin, rifabutin, rifapentine), troleandomycin\r\n*** Itraconazole, ketoconazole\r\n*** Nefazodone\r\n*** Atazanavir, delavirdine, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir, nevirapine\r\n*** Carbamazepine, phenobarbital, phenytoin\r\n* The following medications (including but not limited to) that may alter the concentrations of trametinib or GSK or have their elimination altered by trametinib or GSK should be administered WITH CAUTION:\r\n** USE WITH CAUTION-Drugs potentially affecting trametinib or GSK concentrations\r\n*** Quinidine, diltiazem, verapamil\r\n*** Fluvoxamine, fluoxetine, paroxetine, nefazodone\r\n*** Aprepitant, cimetidine\r\n*** Fluconazole, terbinafine, voriconazole\r\n*** Ciprofloxacin, erythromycin, isoniazid\r\n*** Mibefradil, diltiazem, verapamil\r\n*** Aprepitant, oxandrolone, tizanidine, gemfibrozil\r\n** USE WITH CAUTION-Drugs that may inhibit permeability (P)-glycoprotein (gp) and breast cancer resistance protein (BCRP)\r\n*** Valspodar\r\n*** Atorvastatin\r\n*** Carvedilol\r\n*** Methadone\t\r\n*** Meperidine\t\r\n*** Omeprazole\r\n** USE WITH CAUTION-Drugs that may have their concentrations altered by trametinib or GSK\r\n*** Repaglinide, rosiglitazone, pioglitazone\r\n*** Alfentanil, fentanyl\t\r\n*** Quinidine \r\n*** Cilostazol\r\n*** Astemizole\r\n*** Diergotamine, ergotamine, eletriptan\r\n*** Pimozide\r\n*** Buspirone\r\n*** Felodipine\r\n*** Sildenafil, tadalafil, vardenafil\r\n*** Cerivastatin, lovastatin, simvastatin, atorvastatin\r\n*** Alprazolam, diazepam, midazolam, triazolam\r\n*** Cyclosporine, sirolimus, tacrolimus\r\n*** Cisapride\r\n*** Cyclosporine, torsemide, chloroquine, zopiclone\r\n*** Eplerenone\t\r\n*** Chloroquine, zopiclone\r\n** Use of repaglinide, rosiglitazone and/or pioglitazone is permitted only after consultation with the Cancer Therapy Evaluation Program (CTEP) Medical Monitor
No concomitant treatment, in therapeutic doses, with anticoagulants such as warfarin or warfarin-related agents, heparin, thrombin or factor Xa inhibitors, or antiplatelet agents (e.g., clopidogrel); low dose aspirin (=<  mg/day), low-dose warfarin (=<  mg/day), and prophylactic low molecular weight heparin (LMWH) are permitted; please note that drugs that strongly induce or inhibit cytochrome P family , subfamily A, polypeptide  (CYPA) or are associated with a risk of Torsades are not allowed; chronic concomitant treatment of CYPA inducers is not allowed (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentine, phenobarbital, and St. Johns wort); as part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product; the following drugs are strong inhibitors of CYPA and are not allowed during the treatment with cabozantinib: \r\n* Boceprevir\r\n* Indinavir\r\n* Nelfinavir\r\n* Lopinavir/ritonavir\r\n* Saquinavir\r\n* Telaprevir\r\n* Ritonavir\r\n* Clarithromycin\r\n* Conivaptan\r\n* Itraconazole\r\n* Ketoconazole\r\n* Mibefradil\r\n* Nefazodone \r\n* Posaconazole\r\n* Voriconazole\r\n* Telithromycin\r\n* Drugs with possible or conditional risk of torsades should be used with caution knowing that cabozantinib could prolong the QT interval
Certain medications that act through the cytochrome P (CYP) system are specifically prohibited in patients receiving pazopanib and others should be avoided or administered with extreme caution\r\n* Strong inhibitors of CYPA such as ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole may increase pazopanib concentrations and are prohibited; although, in exceptional circumstances, they may be administered in conjunction with lowering the dose of pazopanib by % of what would otherwise be administered; grapefruit juice is also an inhibitor of CYP and should not be taken with pazopanib\r\n* Strong inducers of CYPA, such as rifampin, may decrease pazopanib concentrations, are strictly prohibited\r\n* Medications that have narrow therapeutic windows and are substrates of CYPA, cytochrome P, family , subfamily D, polypeptide  (CYPD), or cytochrome P, family , subfamily C, polypeptide  (CYPC) should be avoided and, if necessary, administered with caution
The use of potent phospho-glycoprotein (P-gp) inhibitors (including cyclosporine, erythromycin, ketoconazole, itraconazole, quinidine, phenobarbital salt with quinidine, ritonavir, valspodar, verapamil) and potent P-gp inducers (including St John's wort, rifampicin) must be avoided during treatment with afatinib
Patients must not be taking, nor plan to take while on protocol treatment, strong CYPA inhibitors, (e.g. ketoconazole, itraconazole, voriconazole, posaconazole, fluvoxamine, nefazodone, nelfinavir, ritonavir) and/or strong CYPA inducers (e.g. phenytoin, rifampin, rifabutin) within  days prior to randomization (moderate inhibitors or inducers of isoenzyme CYPA should be avoided, but if necessary can be used with caution)
Subject is taking ketoconazole, voriconazole, itraconazole, erythromycin, telithromycin, clarithromycin, rifampin, rifabutin, bromocriptione, cimetidine, cisapride, clotrimazole, danazol, diltiazem, fluconazole, protease inhibitors (e.g., human immunodeficiency virus [HIV] and hepatitis C that include drugs such as ritonavir, indinavir, boceprevir, and telaprevir), metoclopramide, nicardipine, troleandomycin, verapamil, carbamazepine, phenobarbital, phenytoin, rifapentine, St. Johns wort (hypericum perforatum), and grapefruit juice; patients on metformin will not be excluded
Receiving drugs known to be strong inducers of CYPA or inhibiting drugs known to interact with erlotinib including, but not limited to: enzyme-inducing anticonvulsants, rifampicin, rifabutin, St John wort and ketoconazole
Patients taking concurrent medications of any kind which are strong inducers or inhibitors of cytochrome P family , subfamily A, polypeptide  (CYPA); patients receiving any of the following will be excluded: ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns wort
Patients must not be receiving any of the following potent cytochrome P, family , subfamily A, polypeptide  (CYPA) inducers or inhibitors: erythromycin, clarithromycin, azithromycin, ketoconazole, itraconazole, voriconazole, posaconazole, grapefruit juice or St. Johns wort
Strong CYPA inhibitors (e.g. clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telithromycin, voriconazole) or strong CYPA inducers (e.g. carbamazepine, phenobarbital, phenytoin, rifampin, St. Johns Wort) within  days or  drug half-lives (if drug half-life in patients is known), whichever is longer, before start of study treatment
No concomitant treatment, in therapeutic doses, with anticoagulants such as warfarin or warfarin-related agents, heparin, thrombin or Factor Xa inhibitors, or antiplatelet agents (e.g., clopidogrel); low dose aspirin (=<  mg/day), low-dose warfarin (=<  mg/day), and prophylactic low molecular weight heparin (LMWH) are permitted; please note that drugs that strongly induce or inhibit cytochrome P, family , subfamily A, polypeptide  (CYPA) or are associated with a risk of torsades are not allowed; chronic concomitant treatment of CYPA inducers is not allowed (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, and St. Johns wort); as part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product; the following drugs are strong inhibitors of CYPA and are not allowed during the treatment with sorafenib:\r\n* Boceprevir\r\n* Indinavir\r\n* Nelfinavir\r\n* Lopinavir/ritonavir\r\n* Saquinavir\r\n* Telaprevir\r\n* Ritonavir\r\n* Clarithromycin\r\n* Conivaptan\r\n* Itraconazole\r\n* Ketoconazole\r\n* Mibefradil\r\n* Nefazodone\r\n* Posaconazole\r\n* Voriconazole\r\n* Telithromycin\r\n** Drugs with possible or conditional risk of torsades should be used with caution knowing that sorafenib could prolong the QT interval
Patients who are currently being treated with strong cytochrome P family , subfamily A, polypeptide  (CYPA) inhibitors (e.g., amprenavir, fosamprenavir, indinavir, itraconazole, ketoconazole, lopinavir, mibefradil, miconazole, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telaprevir, telithromycin, verapamil, voriconazole, and grapefruit) or strong CYPA inducers (e.g., carbamazepine, felbamate, nevirapine, phenobarbital, phenytoin, primidone, rifabutin, rifampin, rifapentine and St. Johns wort) must either discontinue these drugs or are ineligible
Received cytochrome P A (CYPA) inhibitors (such as fluconazole, ketoconazole and clarithromycin) or inducers (such as rifampin, carbamazapine, phenytoin, St. John's Wort) within  days prior to the first dose of venetoclax
The use of potent permeability glycoprotein (P-gp) inhibitors (including cyclosporine, erythromycin, ketoconazole, itraconazole, quinidine, phenobarbital salt with quinidine, ritonavir, valspodar, verapamil) and potent P-gp inducers (including St John's wort, rifampicin) has to be avoided during treatment with afatinib; any exemptions to this have to be discussed with the principal investigator
Patients using of the following specific inhibitors and inducers of cytochrome P, family , subfamily A, polypeptide  (CYPA) are ineligible; the following inhibitors of CYPA are prohibited within  days before beginning and during treatment with sunitinib: azole antifungals (ketoconazole, itraconazole), diltiazem, clarithromycin, erythromycin, verapamil, delavirdine, and human immunodeficiency virus (HIV) protease inhibitors (indinavir, saquinavir, ritonavir, atazanavir, nelfinavir); the following inducers of CYPA are prohibited within  days before beginning and during treatment with sunitinib: rifampin, rifabutin, carbamazepine, phenobarbital, phenytoin, St. Johns wort, efavirenz, tipranavir; other inhibitors and inducers of CYPA may be used if necessary, but their use is discouraged
Subjects taking the following are not eligible: \r\n* Carbamazepine (e.g., Tegretol) \r\n* Rifabutin (e.g., Mycobutin) or \r\n* Rifampin (e.g., Rifadin) \r\n* Rifapentine (e.g., Priftin) \r\n* St. John's wort \r\n* Clarithromycin (e.g., Biaxin) \r\n* Cyclosporine (e.g. Neoral or Sandimmune) \r\n* Diltiazem (e.g., Cardizem) \r\n* Erythromycin (e.g., Akne-Mycin, Ery-Tab) \r\n* Itraconazole (e.g., Sporanox) \r\n* Ketoconazole (e.g., Nizoral) \r\n* Telithromycin (e.g., Ketek) \r\n* Verapamil (e.g., Calan SR, Isoptin, Verelan) \r\n* Voriconazole (e.g., VFEND) \r\n* Tacrolimus (e.g. Prograf)\r\n* Subjects taking fluconazole, voriconazole, itraconazole, posaconazole, and ketoconazole within  hours of study entry are not eligible; reinstitution of fluconazole, voriconazole, itraconazole, posaconazole, ketoconazole and diltiazem is permissible  hours after the last dose of sirolimus
Concurrent treatment with strong CYPA inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole, grapefruit juice) or inducers (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. John's Wort)
Patients receiving any medications or substances that are strong inhibitors or inducers of cytochrome P, family , subfamily A, polypeptide  (CYP A) are ineligible; caution is advised for patients requiring weak or moderate CYP A inhibitors or inducers; specifically prohibited medicines include indinavir, nelfinavir, ritonavir, clarithromycin, itraconazole, ketoconazole, nefazodone, carbamazepine, phenobarbital, phenytoin, pioglitazone, rifabutin, rifampin, St. John's wort, and troglitazone
Patients CANNOT be receiving enzyme-inducing or enzyme inhibiting agents listed here: Inhibitors: Amiodarone, Amprenavir, Atazanavir, Chloramphenicol, Clarithromycin, Conivaptan, Cyclosporine, Darunavir, Dasatinib, Delavirdine, Diltiazem, Erythromycin, Fluconazole, Fluoxetine, Fluvoxamine, Fosamprenavir, Imatinib, Indinavir, Isoniazid, Itraconazole, Ketoconazole, Lapatinib, Miconazole, Nefazodone, Nelfinavir, Posaconazole, Ritonavir, Quinupristin, Saquinavir, Tamoxifen, Telithromycin, Troleandomycin, Verapamil, Voriconazole; inducers: Aminoglutethimide, Bexarotene, Bosentan, Carbamazepine, Efavirenz, Fosphenytoin, Griseofulvin, Modafinil, Nafcillin, Nevirapine, Oxcarbazepine, Phenobarbital, Phenytoin, Primidone, Rifabutin, Rifampin, Rifapentine, St. Johns wort, Sulfadimidine, Sulfinpyrazone, Troglitazone, Troleandomycin; all concomitant medications must be recorded
Patients who have had chemotherapy, radiotherapy or oral antifungal agents (ketoconazole, itraconazole, fluconazole) within  weeks prior to entering the study or those who have not recovered (e.g. back to baseline or grade ) from adverse events due to agents administered more than  weeks earlier\r\n* There is a potential drug interaction when abiraterone is concomitantly used with a cytochrome P family , subfamily D, polypeptide  (CYPD) substrate narrow therapeutic index (e.g., thioridazine, dextromethorphan), or strong cytochrome P family , subfamily A, polypeptide  [CYPA] inhibitors (e.g., atazanavir, erythromycin, indinavir, itraconazole, Ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, and voriconazole) or strong inducers (e.g., carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin, rifapentine); caution should be used when patients are on one of these drugs
Patients cannot have received cytochrome P-inducing anticonvulsants (enzyme-inducing antiepileptic drugs [EIADs]; e.g., phenytoin, carbamazepine, phenobarbital, primidone, oxcarbazepine) or similar agents (e.g., rifampin) or P inhibiting agents (ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole) within  days prior to starting lapatinib
Patients currently receiving treatment with strong cytochrome P, family , subfamily A, polypeptide  (CYPA) inhibitors who cannot discontinue such treatment or be switched to a different medication prior to starting study drug are excluded from study entry; strong CYPA inhibitors include the following medications: itraconazole, ketoconazole, miconazole, voriconazole; amprenavir, atazanavir, fosamprenavir, indinavir, nelfinavir, ritonavir; ciprofloxacin, clarithromycin, diclofenac, doxycycline, enoxacin, isoniazid, ketamine, nefazodone, nicardipine, propofol, quinidine, telithromycin
Inhibitors of P-glycoprotein efflux transporters\r\n* Concomitant medications that are strong inhibitors of P-glycoprotein efflux transporters should be used with caution during the study; examples of these medications include ritonavir, cyclosporine, verapamil, erythromycin, ketoconazole, itraconazole, quinidine, and elacridar
The following medications may not be taken within  hours of the first dose of study agent or at any time while a participant is taking study agent\r\n* Coumadin\r\n* Strong CYPA inhibitors including ketoconazole, atazanavir, boceprevir, ceritinib, clarithromycin, cobicistat, darunavir, dasabuvir, idelalisib, indinavir, itraconazole, lopinavir, nefazodone, nelfinavir, ombitasvir, paritaprevir, posaconazole, ritonavir, saquinavir, telithromycin, troleandomycin, voriconazole, and grapefruit or grapefruit juice\r\n* CYPA inducers including rifampicin, rifabutin, rifapentine, phenytoin, carbamazepine, phenobarbital, primidone, enzalutamide, fosphenytoin, lumacaftor, mitotane, and St. John's wort\r\n* Agents which decrease gastric acid are allowed but should be avoided if possible\r\n* Participants may resume inhibitors or inducers of CYPA >  days after their last dose of study agent
Participants currently receiving zidovudine, or strong CYPA inhibitors (e.g. cobicistat (currently only in Stribild or ritonavir boosted antiretroviral regimens), ketoconazole, itraconazole, erythromycin, clarithromycin, dexamethasone, phenobarbital, rifampin, phenytoin, carbamazepine, rifabutin, rifapentine, St Johns Wort, tacrolimus, cyclosporine, oral contraceptives, warfarin, docetaxel, sirolimus, or other strong inhibitors or inducers of CYPA or substrates of CYPA that have a narrow therapeutic margin
Concurrent use of:\r\n* Strong CYPA inhibitors: including but not limited to ketoconazole, itraconazole, clarithromycin, atazanavir, nefazodone, saquinavir, telithromycin, ritonavir, amprenavir, indinavir, nelfinavir, delavirdine and voriconazole\r\n* Strong CYPA inducers: including but not limited to rifampin, rifabutin, rifapentine, phenobarbital, phenytoin, carbamazepine, and St. John's wort\r\n* Therapeutic doses of anticoagulants (low dose warfarin up to  mg daily for DVT prophylaxis is permitted)\r\n* Grapefruit and grapefruit juice\r\n**(Note: Alternative therapies should be used when available; if use of a strong CYPA inhibitor or inducer is necessary, this must be approved by the principal investigator and documented in source documents)
Are taking strong cytochrome P (CYP) CYPA inhibitors (eg, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telithromycin, voriconazole) or strong CYPA inducers (eg, carbamazepine, phenobarbital, phenytoin, rifampin, St. John's Wort).
Palbociclib is a substrate of cytochrome P, family , subfamily A (CYPA); caution should be exercised when dosing palbociclib concurrently with CYPA inducers or inhibitors; furthermore, patients who are taking concurrent medications that are strong inducers/inhibitors or substrates of CYPA should be switched to alternative medications to minimize any potential risk; the following medications with strong potential for interaction are not allowed: indinavir, nelfinavir, ritonavir, clarithromycin, itraconazole ketoconazole, nefazodone, saquinavir, telithromycin, carbamazepine, phenobarbital, phenytoin, pioglitazone, rifabutin, rifampin, St. John's wort, troglitazone
Concomitant use of phenytoin, carbamazepine, barbiturates, rifampicin, phenobarbital, or St John's wort, alfentanil, alfuzosin, almotriptan, alprazolam, amiodarone, amitriptyline, amprenavir, aprepitant, aripiprazole, bepridil, bortezomib, bosentan, budesonide, buprenorphine, buspirone, carbamazepine, cilostazol, cisapride, cyclosporine, delavirdine, didanosine, digoxin, disopyramide dofetilide, donepezil, eletriptan, eplerenone, fluticasone, fosamprenavir, galantamine, systemic griseofulvin, indinavir, levobupivacaine, lopinavir, midazolam, mifepristone, modafinil, nateglinide, nefazodone, nelfinavir, oxcarbazepine, pimozide, quetiapine, quinidine, repaglinide, rifabutin, rifampin, rifapentine, ritonavir, saquinavir, sildenafil, sirolimus, tacrolimus, tadalafil, tolterodine, theophyllines, tolterodine, triazolam, valdecoxib, vardenafil, ziprasidone, zonisamide, statins, with the exception of pravastatin (Pravachol) or other \statins\ which are not metabolized by or induce cytochrome P, family , subfamily A, polypeptide  (CYPA), calcium channel blockers, Coumadin and macrolides or other agents that will be significantly perturbed in a clinically important way by the P inhibitory properties of ketoconazole
Patients must not be receiving any of the following potent cytochrome P, family , subfamily A, polypeptide  (CYPA) inducers or inhibitors: erythromycin, clarithromycin, ketoconazole, azithromycin, itraconazole, grapefruit juice or St. John's Wort
Taking strong inhibitors or strong/moderate inducers of cytochrome P (CYP)A\r\n* Strong inhibitors of CYPA/; > -fold increase in the plasma area under the curve (AUC) values or more than % decrease in clearance\r\n** Clarithromycin (Biaxin, Biaxin XL)\r\n** Conivaptan (Vaprisol)\r\n** Grapefruit juice\r\n** Itraconazole (Sporanox)\r\n** Ketoconazole (Nizoral)\r\n** Mibefradil\r\n** Nefazodone (Serzone)\r\n** Posaconazole (Noxafil)\r\n** Telaprevir (Incivek)\r\n** Telithromycin (Ketek)\r\n* Use of the following inducers are prohibited =<  days prior to registration\r\n** Strong inducers of CYPA/; > % decrease in AUC\r\n*** Avasimibe\r\n*** Carbamazepine (Carbatrol, Epitol, Equetro, Tegretol, Tegretol-XR)\r\n*** Phenytoin (Dilantin, Phenytek)\r\n*** Rifampin (Rifadin)\r\n*** St. Johns wort\r\n** Moderate inducers of CYPA/; -% decrease in AUC\r\n*** Bosentan (Tracleer)\r\n*** Modafinil (Provigil)\r\n*** Nafcillin\r\n*** Phenobarbital (Luminal)\r\n*** Rifabutin (Mycobutin)\r\n*** Troglitazone
Use of ketoconazole, itraconazole, ritonavir, cyclosporine, carbamazepine, phenytoin, phenobarbital within  weeks prior to and while on study therapy
Currently on enzyme inducing anti-convulsants or other strong inducers (efavirenz, nevirapine, barbiturates, carbamazepine, modafinil, phenobarbital, phenytoin, rifabutin, rifampin, pioglitazone, St. Johns wort) or strong inhibitors of cytochrome P, family , subfamily A, polypeptide  (CYPA) (indinavir, nelfinavir, ritonavir, clarithromycin, itraconazole, voriconazole, ketoconazole, nefazodone, saquinavir, telithromycin)
Patients receiving medications that may increase risk of rhabdomyolysis such as itraconazole, ketoconazole, erythromycin, cyclosporine, amiodarone, verapamil, clarithromycin, nefazodone, ranolazine, human immunodeficiency virus (HIV) protease inhibitors, gemfibrozil, posaconazole, danazol, amiodarone, diltiazem, and amlodipine
Are taking strong cytochrome P (cytochrome P, family , subfamily A, polypeptide  [CYPA]) inhibitors (e.g., clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telithromycin, voriconazole) or strong CYPA inducers (e.g., carbamazepine, phenobarbital, phenytoin, rifampin, St. Johns wort/Hypericum perforatum)
Patients who need to take CYPA inhibitors, such as cyclosporine, sirolimus, tacrolimus, verapamil, danazol, gemfibrozil, ketoconazole, or macrolide antibiotics (e.g., azithromycin, clarithromycin, erythromycin) will be excluded; prior use of these agents is acceptable, as long as they are stopped at least a week prior to study entry
Concurrent treatment with any medications or substances that are potent inhibitors or inducers of cytochrome P family , subfamily A, polypeptide  (CYPA), hepatic enzyme inducing antiepileptic drugs (EIAEDs), or other drugs known to affect the metabolism of modafinil; examples include, but are not limited to, itraconazole, ketoconazole, doxycycline, rifampin, St. John's wort, phenytoin, phenobarbital, diazepam, and tricyclic antidepressants\r\n* If patients were previously taking EIAEDs, they must be off for >  weeks prior to study enrollment
Patients taking significant cytochrome P family , subfamily A, polypeptide  (CYPA) inhibitors or inducers, i.e. protease inhibitors (ritonavir, nelfinavir, etc), clarithromycin, ketoconazole, fluconazole, verapamil, diltiazem, carbamazepine, phenytoin, phenobarbital, Rifampin, efavirenz, nevirapine
Need for medications that are strong cytochrome P, family , subfamily A (CYPA) inhibitors (e.g. ketoconazole, itraconazole, clarithromycin, nefazodone, nelfinavir, ritonavir, indinavir, saquinavir), moderate CYPA inhibitors (e.g. diltiazem, verapamil, erythromycin, fluconazole), CYPA inducers (e.g. rifampin, rifabutin, rifapentine, phenobarbital, phenytoin, carbamazepine, St. Johns wort), CYPA substrates with a narrow therapeutic range (e.g. cyclosporine, tacrolimus, sirolimus), P-glycoprotein (P-gp) inhibitors or substrates (e.g. cyclosporine, digoxin), cytochrome P, family , subfamily D, polypeptide  (CYPD) substrates (e.g. tricyclic antidepressants and antipsychotics),or simvastatin at doses >  mg/day within  days of the first planned ranolazine dose
Prior or current use of statin medication, or current use of gemfibrozil, cyclosporine, danazol, lomitapide, verapamil, diltiazem, dronedarone, amiodarone, amlodipine, ranolazine, or strong cytochrome P, family , subfamily A, polypeptide  (CYPA) inhibitors (e.g., itraconazole, ketoconazole, posaconazole, voriconazole, human immunodeficiency virus [HIV] protease inhibitors, boceprevir, telaprevir, erythromycin, clarithromycin, telithromycin, nefazodone, or cobicistat-containing products)
Current systemic use of medications known to interact with statins and potentially increase toxicity, including gemfibrozil, cyclosporine, danazol, lomitapide, verapamil, diltiazem, dronedarone, amiodarone, amlodipine, ranolazine, strong CYPA inhibitors (e.g., itraconazole, ketoconazole, posaconazole, voriconazole, human immunodeficiency virus [HIV] protease inhibitors, boceprevir, telaprevir, erythromycin, clarithromycin, telithromycin, nefazodone, or cobicistat-containing products), or strong CYPA inducers (e.g., carbamazepine, phenytoin, rifampin, St. Johns wort, bosentan, efavirenz, etravirine, modafinil, nafcillin)
Women currently taking strong cytochrome P family  subfamily A member  (CYPA) inducers or inhibitors; drugs that cannot be coadministered with rapamycin include but are not limited to: calcium channel blockers: nicardipine, antifungal agents: clotrimazole, fluconazole, antibiotics: troleandomycin, gastrointestinal prokinetic agents: cisapride, metoclopramide; other drugs: bromocriptine, cimetidine, danazol, human immunodeficiency virus (HIV)-protease inhibitors (e.g., ritonavir, indinavir), anticonvulsants: carbamazepine, phenobarbital, phenytoin, antibiotics: rifapentine